A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body
and removed over time) and safety of a single dose of ceftobiprole in pediatric patients
undergoing treatment with systemic antibiotics and may be used to guide dosing
recommendations for ceftobiprole in children.
Phase:
Phase 1
Details
Lead Sponsor:
Basilea Pharmaceutica
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.